Citius Pharmaceuticals Reports $1.67M Revenue in Q2 2026, Faces $28.11M Net Loss

Citius Pharmaceuticals, Inc. reported its financial results for the second quarter of fiscal year 2026, revealing a revenue of $1.67 million for the three months ended March 31, 2026, compared to no revenue in the same period last year. The company attributed this revenue to the commercial launch of its oncology product, LYMPHIR, which began distribution in December 2025. For the six-month period, total revenue reached $5.61 million, with a gross profit margin of approximately 80%. However, the company also reported a net loss of $28.11 million for the quarter, significantly higher than the $11.51 million loss recorded in the prior year, primarily due to increased operating expenses.

Operating expenses surged to $33.53 million for the three months ended March 31, 2026, up from $11.26 million in the same quarter of the previous year. This increase was largely driven by a $19.73 million contract cancellation fee related to a terminated agreement with a contract manufacturing organization, alongside higher general and administrative costs. Research and development expenses decreased to $1.63 million from $3.77 million year-over-year, reflecting reduced costs associated with ongoing projects.

Citius Pharmaceuticals also reported significant changes in its balance sheet. As of March 31, 2026, the company had total assets of $132.54 million, up from $130.94 million at the end of the previous fiscal year. Cash and cash equivalents increased to $4.59 million, while current liabilities rose to $55.02 million, leading to a negative working capital of approximately $23.3 million. The company’s accumulated deficit reached $268.26 million, highlighting ongoing financial challenges.

Strategically, Citius has been active in expanding its market presence. The company announced the initial shipment of LYMPHIR to Europe, marking a significant step in its international distribution efforts. Additionally, Citius Oncology, a majority-owned subsidiary, secured a loan agreement for up to $25 million to support its operations, with $10 million already funded. The company is also engaged in capital-raising initiatives to extend its cash runway beyond November 2026, as it anticipates needing additional funds to support ongoing operations and product development.

Looking ahead, Citius Pharmaceuticals remains focused on increasing the adoption of LYMPHIR and expanding its market access. The company has reported positive early metrics from its commercial launch, including strong institutional uptake and broad payer coverage. However, it acknowledges the need for substantial additional financing to continue its operations and meet its financial obligations, raising concerns about its ability to sustain operations in the long term without further capital.